Latest news with #AIML
Associated Press
5 days ago
- Business
- Associated Press
AIML Subsidiary Neural Cloud Signs LOI with Circular Health to License MaxYield(TM) ECG Signal Processing
Letter of Intent: Circular Health Limited to Enhance ECG Smart Ring with AI-Powered Signal Clarity with multi‑year, per‑user SaaS license targeting commercial launch by September 2025. Global growth catalyst: The collaboration positions both companies to scale AI‑enhanced cardiac monitoring and next-gen health intelligence across new geographies and device form factors. Economic and Clinical Benefits: MaxYield(TM) is expected to improve ECG signal quality, increase the amount of usable data, and provide deeper biometric insights for Circular Health's wearable platform. TORONTO, ON / ACCESS Newswire / June 3, 2025 / AI/ML Innovations Inc. ('AIML' or the 'Company') (CSE: AIML)(OTCQB: AIMLF)(FWB: 42FB) is pleased to announce that its subsidiary Neural Cloud Solutions Inc. has executed a Letter of Intent (LOI) with Circular Health Limited of Paris to integrate and license Neural Cloud's flagship ECG signal‑processing platform, MaxYield™. Circular Health Limited, is a wearable health technology company redefining personalized health with its next-generation smart ring-Circular Ring 2-equipped with ECG capabilities, advanced sensors, and an AI-driven app featuring wellness assistant Kira. This device will offer unique heart rhythm monitoring as part of their mission to empowers users to proactively manage their health. Under the LOI, Circular Health will deploy MaxYield through a cloud-based API during the integration phase leading up to launch. The integration will enable clearer, more interpretable ECG signals and support consumer access to cardiac visualization and insights. The parties intend to finalize a definitive Software License Agreement and target a commercial launch by September 2025. Why MaxYield™ Matters for Circular Health Higher data yield: A cleaner signal allows Circular Health to capture more usable data and enhance measurement precision, unlocking richer biometric insights from every minute of ECG use across its wearable ecosystem. Scalable workflow: The per‑user SaaS model aligns cost with growth, supporting Circular Health's expansion into new geographies and device form factors. Resource redeployment: Automated noise-handling and ECG processing allows clinical and data‑science staff to shift focus from in-house signal cleaning to additional higher‑value analytics and patient engagement. Expansion into New Markets: As MaxYield™ progresses through the FDA 510(k) pipeline, Circular is poised to access additional medically relevant markets, particularly in Remote Patient Monitoring and Clinical Trials. Management Commentary Peter Kendall - President & Chief Commercialization Officer, AIML 'This LOI validates the commercial scalability of MaxYield and our ability to partner with innovative digital‑health companies around the globe. We look forward to helping Circular Health deliver best‑in‑class ECG clarity to its users.' Esmat Naikyar - Chief Product Officer, AIML / President, Neural Cloud Solutions 'By automating the most time‑consuming part of ECG workflows, MaxYield lets Circular Health redeploy resources to deeper analytics and product differentiation. We anticipate that higher‑quality, higher‑volume data will translate into stronger predictive models and better health outcomes.' Laurent Bsalis - Director, Circular Health Limited 'We're excited to collaborate with AIML to bring enhanced ECG signal clarity and comprehensive beat detection to our next-generation ring,' said Laurent Bsalis, Director of Circular Health Limited. 'Together, we aim to redefine what wearable technology can deliver in proactive and personalized health tracking.' For more information about AIML: For detailed information please see AIML's website or the Company's filed documents at . Contact: Blake Fallis (778) 405-0882 [email protected] About AIML Innovations Inc. AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care. With a growing portfolio of regulatory filings, including a 510(k) premarket notification and a registered FDA Device Master File, AIML is committed to rigorous validation and broad interoperability. AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB). On behalf of the Board of Directors: Paul Duffy, Executive Chairman and CEO Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. SOURCE: AI/ML Innovations, Inc. press release
Hans India
5 days ago
- Business
- Hans India
BVCITS students enter IEEE YESIST12 finals
Amalapuram (Konaseema district): A team of first year AIML students of Bonam Venkata Chalamayya Institute of Technology and Science (BVCITS) has secured a place in the final round of IEEE YESIST12 2025 Innovation Challenge. The project, titled 'Fresh Water Futures', developed by students V Manisree, K Leela, A Pallavi, and C Asrutha, has earned international recognition for its innovative approach and technical excellence. The final round of the competition will be held at IEEE UKM Student Branch in Malaysia on August 23 and 24. The college management announced that all necessary support would be extended to the team to ensure their participation and success at the global stage. Students were congratulated at a special meeting held at the college to celebrate the achievement. College Secretary Bonam Kanakayya, Chairman Bonam Krishna Satish, Principal Dr JVG Rama Rao, AO J Krishna Rao, Pilot Head Sarma Adithe, Coordinator DV Satish, and mentors Vamsi Ram and Bhavani, along with IEEE YESIST12 Ambassador Vijay Surya, commended the students for their dedication and hard work. 'This is a remarkable achievement that brings honour to our institution and highlights the immense talent of our students,' said College Chairman Bonam Krishna Satish. The college management further expressed hope that this success would inspire more students to participate in global innovation platforms and bring laurels to the institute.
News18
29-05-2025
- News18
Engineering Student Dies By Suicide In Karnataka, Mentions 'Academic Pressure' In Note
Last Updated: The Kodagu Police found a found a suicide note from the scene in which Tejaswini had reportedly stated that she was ending her life due to academic pressure. In a tragic incident, a first-year engineering college student died by suicide in her hostel room in Karnataka's Kodagu district. The student, identified as Tejaswini (19), was a first-year Artificial Intelligence and Machine Learning (AIML) student at Halligattu CET College in Ponnampet. The Kodagu Police found a found a suicide note from the scene in which Tejaswini had reportedly stated that she was ending her life due to academic pressure. She said had six academic backlogs and did not wish to continue her studies, news agency ANI reported. Tejaswini was the only daughter of Mahantappa, a resident of Raichur, in northeastern Karnataka. According to India Today report, the deceased recently celebrated her 19th birthday with her friends. On Wednesday, she reportedly distributed sweets again to those who were unable to attend her birthday celebration. Around 4:30 PM, a classmate noticed Tejaswini's room door was locked from the inside. After getting no response from knocks or calls, the hostel supervisor was alerted. They forced the door open and found Tejaswini unresponsive. A note mentioning academic pressure was discovered nearby. First Published:
Associated Press
22-05-2025
- Business
- Associated Press
AI/ML Establishes Innovation Committee, Appoints Dr. Drew Dundas as Chair
TORONTO, ON / ACCESS Newswire / May 22, 2025 / AI/ML Innovations Inc. ('AIML' or the 'Company') (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) today announced the formation of its Innovation Committee, a committee of the Board of Directors of AIML, created to provide strategic oversight of the Company's regulatory filings, intellectual‑property roadmap, and product‑development initiatives. Dr. Drew Dundas, an internationally recognized medical‑device innovator and director of AIML, has been appointed Chair of the Innovation Committee. Dr. Drew Dundas: Deep Clinical & Commercial Expertise Dr. Dundas brings more than 25 years of experience in translational research, FDA submissions, and product commercialization. As the Chief Technology Officer at Earlens Corporation, he led the team that secured clearance for the world's first non-surgical, contact drive hearing device. He has authored over 70 papers, has been an invited speaker at multiple international scientific conferences, holds multiple patents in signal processing, fitting prescription and biomedical sensing, and has guided several early‑stage health‑tech firms from concept through regulatory approval and market launch. In his new role, Dr. Dundas will collaborate with AIML's executive team to: Dr. Drew Dundas - Director and Innovation Committee Chair: 'AIML's technology addresses one of healthcare's greatest challenges: extracting clean, actionable signals from the physiologic and environmental noise of real‑world data. I'm honored to lead the Innovation Committee and help ensure that our regulatory, IP, and product development strategies translate this important technology into global clinical impact.' Paul Duffy - CEO & Executive Chairman, AIML: 'Formalizing the Innovation Committee underscores AIML's commitment to disciplined governance as we scale. Drew's expertise fortifies our board and positions us to deliver sustained value to clinicians, partners, and shareholders.' For more information about AIML: For detailed information please see AIML's website or the Company's filed documents at Contact: Blake Fallis (778) 405-0882 [email protected] About AIML Innovations Inc. AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care. With a growing portfolio of regulatory filings, including a 510(k) premarket notification and a registered FDA Device Master File, AIML is committed to rigorous validation and broad interoperability. AIML's shares trade on the Canadian Securities Exchange (CSE: AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB). On behalf of the Board of Directors: Paul Duffy, Executive Chairman and CEO Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. SOURCE: AI/ML Innovations, Inc. press release
Associated Press
25-04-2025
- Business
- Associated Press
AIML Innovations Announces Departure of Tim Daniels from Board of Directors
• Tim Daniels to Continue Supporting AIML in an Advisory Capacity VANCOUVER, BC / ACCESS Newswire / April 25, 2025 / AI/ML INNOVATIONS INC. ('AIML' OR THE 'COMPANY') (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) announces that Tim Daniels has stepped down from his position on the Company's Board of Directors ('Board'), effective immediately. Tim has been an integral part of AIML's leadership, contributing to the Company's strategic direction and governance during his tenure on the Board. His insights and dedication have played a key role in guiding AIML through important phases of growth and evolution. Paul Duffy, CEO of AIML, commented: 'On behalf of the entire team at AIML, I would like to extend our sincere thanks to Tim for his contributions and leadership. We are pleased that Tim will continue to support the Company in an advisory capacity, where his experience and counsel will remain a valued asset as we advance our mission in AI-driven healthcare.' AIML remains focused on strengthening its leadership and advisory network to support ongoing commercialization efforts and strategic growth initiatives. For more information about AIML: For detailed information please see AIML's website or the Company's filed documents at Contact: Blake Fallis (778) 405-0882 [email protected] About AI/ML Innovations Inc. AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its wholly owned subsidiaries, NeuralCloud Solutions Inc, Quantum Sciences Ltd, and AI Rx Inc., strategic partnerships with Health Gauge Inc. (95.2% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AIML's shares are traded on the Canadian Securities Exchange under the symbol 'AIML', the OTCQB Venture Market under 'AIMLF', and the Frankfurt Stock Exchange under '42FB'. On behalf of the Board of Directors: Paul Duffy, Chairman Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. SOURCE: AI/ML Innovations, Inc. press release
